Clinical Trial

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously administered LTG-001 in healthy male and female participants
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-17
notable Primary completion pushed: 2026-04-28 -> 2026-09 2026-06-17
minor Completion pushed: 2026-04-28 -> 2026-09 2026-06-17
Trial Details
NCT Number NCT06049095
Lead Sponsor Latigo Biotherapeutics
Conditions Healthy
Enrollment 204 participants
Start Date 2023-10-17
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-16